Literature DB >> 30107016

Disease-modifying therapies for nonrelapsing multiple sclerosis: Costs and benefits of medical intervention.

David E Jones1.   

Abstract

Year:  2013        PMID: 30107016      PMCID: PMC6082358          DOI: 10.1212/01.CPJ.0000436214.18755.af

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


× No keyword cloud information.
  5 in total

1.  The American Academy of Neurology's top five choosing wisely recommendations.

Authors:  Annette M Langer-Gould; Wayne E Anderson; Melissa J Armstrong; Adam B Cohen; Matthew A Eccher; Donald J Iverson; Sonja B Potrebic; Amanda Becker; Rod Larson; Alicia Gedan; Thomas S D Getchius; Gary S Gronseth
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

Review 2.  Glatiramer acetate for multiple sclerosis.

Authors:  Loredana La Mantia; Luca M Munari; Roberta Lovati
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

Review 3.  Interferon beta for secondary progressive multiple sclerosis.

Authors:  Loredana La Mantia; Laura Vacchi; Carlo Di Pietrantonj; George Ebers; Marco Rovaris; Sten Fredrikson; Graziella Filippini
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

Review 4.  Progressive multiple sclerosis.

Authors:  Monika Bradl; Hans Lassmann
Journal:  Semin Immunopathol       Date:  2009-11       Impact factor: 9.623

5.  Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

Authors:  Afsaneh Shirani; Yinshan Zhao; Mohammad Ehsanul Karim; Charity Evans; Elaine Kingwell; Mia L van der Kop; Joel Oger; Paul Gustafson; John Petkau; Helen Tremlett
Journal:  JAMA       Date:  2012-07-18       Impact factor: 56.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.